

SYNTHESIS, CHARACTERIZATION, *IN SILICO* OPTIMIZATION, AND CONFORMATIONAL STUDIES OF METHYL 4-*O*-PIVALOYL- α -L-RHAMNOPYRANOSIDES

Mohammed Mahbubul Matin^{1a*}, Mohammad Ibrahim^{2a}, Tasnim Rahman Anisa^{3a}, and Md. Rezaur Rahman^{4b}

^aBioorganic and Medicinal Chemistry Laboratory, Department of Chemistry, Faculty of Science, University of Chittagong, Chattogram 4331, BANGLADESH. E-mail: mahbubchem@cu.ac.bd¹; mibrahim2007cu@gmail.com²; tani72762@gmail.com³

^bDepartment of Chemical Engineering and Energy Sustainability, Faculty of Engineering, Universiti Malaysia Sarawak, Jalan Datuk Mohammad Musa, Kota Samarahan, 94300, Malaysia. E-mail: rmrezaur@animas.my⁴

*Corresponding Author: mahbubchem@cu.ac.bd

Received: 18th Jul 2021

Accepted: 23rd Sep 2021

Published: 28th Feb 2022

DOI: <https://doi.org/10.22452/mjs.vol41no1.6>

ABSTRACT Considering promising biological activities of natural and synthetic rhamnopyranoside esters, we have synthesized several methyl 4-*O*-pivaloyl- α -L-rhamnopyranosides *via* selective 2,3-*O*-acetonide protection of methyl α -L-rhamnopyranoside (**4**) followed by C-4 pivaloylation, and deprotection. The synthesized 4-*O*-pivaloate **7** and its 2,3-di-*O*-esters **8a-e** are characterized by spectroscopy and are optimized by using density functional theory (DFT). The free energy and bond angles thus calculated are used to establish the probable conformation(s). The 2,3-*O*-acetonide protected rhamnopyranosides **5-6** are found to be slightly distorted from the regular ¹C₄ conformation, and exist between the chair and twist-boat (skew) conformation while other pivaloyl esters **7-8a-e** exist in regular ¹C₄ chair conformation.

Keywords: Conformational study, DFT optimization, Methyl α -L-rhamnopyranoside, Pivaloyl esters, Protection-deprotection method.

1. INTRODUCTION

Carbohydrates are the most ubiquitous of all biological molecules, which play a pivotal role in many biological processes, and yet some of the least are understood (Gregurick et al., 1999). Unfortunately, several natural carbohydrate compounds possess poor binding affinities and pharmacokinetic properties (Hevey, 2019). Hence, their structural modification improves their applicability in various fields including drug candidates (Dhvale & Matin, 2005; Matin, 2006). Carbohydrate esters, especially monosaccharide-based sugar

esters (SEs), exhibited diverse biological functions in all kinds of organisms (Matin et al., 2005). The presence of one or more lipophilic moieties (ester parts) and hydrophilic carbohydrate moiety improves their biodegradability, non-toxicity, and wide range of industrial and medicinal applications (Awwal, 2017; Matin et al., 2019a; Kazmi et al., 2012; Matin et al., 2020a). For instance, the solubility and anti-carcinogenic properties of glucose aspirin ester (**1**, Figure 1) were improved eight to seven-fold and nine-fold, respectively, in comparison with original aspirin (Jacob & Tazawa, 2012).

Among the bioactive SEs, natural and synthetic rhamnopyranoside derived esters were found to be at the exigent level of importance due to chromogenic (Zhang et al., 2008), promising antimicrobial (Matin & Ibrahim, 2010; Kabir et al., 2002), antiviral (Matin et al., 2020b) and pharmacological properties (Matin, 2014; Matin et al., 2008). For example, naturally occurring novel rhamnopyranose esters (e.g. **2a-d**) exhibited excellent scaffolds for triple-negative breast cancer suppressive agents with very low IC₅₀ values (4.95 μM) (Elmaidomy et al., 2020). L-Rhamnose derived dendron could display multivalent

interactions with antibodies in anticancer immunotherapy (Alsarraf et al., 2020). The pyranonaphthoquinone antibiotics such as nanaomycin D, granaticin, kalafungin, and medermycin (**3**, Figure 1) contain methyl α-L-rhamnopyranoside (**4**; methyl 6-deoxy-α-L-mannopyranoside) as an important constituent which also renders improved antimicrobial, and antitumor activities with enhanced solubility (Shalaby et al., 1994a). Rhamnopyranoside esters can also be used for synthetic intermediates, and related bioactive products (Yadav et al., 2013).




Figure 1. Pharmacologically active SEs **1**, **2a-d** and **3**.

However, esterification of rhamnopyranoside **4** at a certain position is always not possible as it contains three secondary hydroxyl groups of similar reactivity. It generally produces a mixture of mono-, di- and tri-*O*-acyl esters (Lawandi et al., 2016). Several methods such as direct (Kabir & Matin, 1996; Matin et al., 2020c), dibutyltin oxide (DBTO) (Kabir & Matin, 1994; Kabir & Matin, 1997), enzymatic (Luo et al., 2013), and catalytic methods (Liu et al., 2017; Matin et al., 2019b) were employed in the past decades. They have both advantages and shortcomings. In addition, their structural characterization is tedious and needs different analytical methods simultaneously (Bukowicki et al., 2015). It was observed (Kabir et al., 2003) that selective unimolar acylation of **4** employing both the direct and DBTO

methods furnished regioselectivity at C-3 position only. Nevertheless, many bioactive rhamnopyranosides possess ester/substituents at the C-4 position. Keeping this in mind, we adopted the protection-deprotection technique (Matin et al., 2016) for esterification at the C-4 position, and reported herein. Many researchers reported that rhamnopyranoside **4** and its tri-*O*-acyl esters have ¹C₄ conformation (Shalaby et al., 1994b). However, the incorporation of an isopropylidene ring between 2-OH and 3-OH positions along with bulky ester moieties might have changed their conformations. Hence, for conformational investigation, all the synthesized rhamnopyranosides **5-7** and **8a-e** are optimized by using DFT (density functional theory). The resulting conformations and molecular orbital properties are reported here.

2. EXPERIMENTAL

2.1. General methods and techniques

The chemicals and solvents used for the synthesis were commercially available (Aldrich), and were used as received. Some solvents were distilled before use. TLC (thin layer chromatography) was conducted on prepared silica gel plates (Kieselgel GF₂₅₄) and visualized by spraying 1% sulphuric acid with methanol followed by heating ~200 °C until the appearance of a blackish colour. Column chromatography (CC) was performed with silica gel G₆₀ in different solvent systems and is duly mentioned. Infrared spectra of the compounds were taken on an FT-IR (IRPrestige-21 spectrophotometer, Shimadzu Scientific Instruments) in chloroform solution. Both the ¹H NMR and ¹³C NMR spectra (Bruker DPX-400 spectrometer, Switzerland) were scanned in CDCl₃ solution. Delta (δ) scale (ppm, reference tetramethylsilane) was used for the chemical shifts. Coupling constant (*J*) values are presented in Hz. Elemental analyses (EA) were performed with a C,H-analyser (EuroVector, EA3100).

2.2. Synthesis of the compounds

Methyl 2,3-*O*-isopropylidene- α -L-rhamnopyranoside (**5**): This mono-acetonide **5** was synthesized from methyl α -L-rhamnopyranoside (**4**) by treating with DMP (2,2-dimethoxypropane, as solvent and reagent) with catalytic *p*-toluenesulphonic acid in 96% as a clear thick liquid according to reported procedure (Yadav et al., 2013; Lawandi et al., 2016).

Methyl 4-*O*-pivaloyl-2,3-*O*-isopropylidene- α -L-rhamnopyranoside (**6**): Pivaloyl chloride (1.824 g, 15.127 mmol) was added to a cooled solution of mono-acetonide **5** (3.0 g, 13.745 mmol) in dry pyridine (12 mL) followed by addition of catalytic amount of DMAP. After 12 h the

reaction mixture was quenched with ice-water and extracted with organic solvent (DCM) in a separating funnel. Concentration of the combined extracts followed by CC purification gave pivaloyl ester **6** (4.076 g, 98%) as syrup. *R*_f = 0.48 (Petroleum ether (PE)-ethyl acetate = 10:1); FT-IR (CHCl₃): 1738 cm⁻¹ (CO); ¹H NMR (400 MHz, CDCl₃): δ_H 4.85 (s, 1H), 4.79 (dd, *J* = 10.1 and 7.3 Hz, 1H), 4.05-4.11 (m, 2H), 3.63-3.70 (m, 1H), 3.43 (s, 3H), 1.51 (s, 3H), 1.28 (s, 3H), 1.17 (s, 9H), 1.11 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ_C 177.4, 109.7, 98.0, 75.9(2), 74.1, 63.9, 54.9, 38.7, 27.6, 26.4, 27.1(3), 17.0; Anal. Calcd. for C₁₅H₂₆O₆ (302.37): C, 59.58; H, 8.67. Found: C, 59.66; H, 8.73.

Methyl 4-*O*-pivaloyl- α -L-rhamnopyranoside (**7**): Reaction of the mono-ester **6** (3.0 g, 9.922 mmol) with AcOH (96%) (20 mL) below 40 °C was conducted for 9-10 h. Usual concentration, co-evaporation with toluene followed by chromatographic purification gave pivaloate **7** (2.160 g, 83%) as a thick liquid. *R*_f = 0.49 (PE-ethyl acetate = 1:1); FT-IR (CHCl₃): 3440-3190 (OH), 1739 cm⁻¹ (CO); ¹H NMR (400 MHz, CDCl₃): δ_H 4.75 (t, *J* = 9.8 Hz, 1H), 4.70 (s, 1H), 3.90 (d, *J* = 3.4 Hz, 1H), 3.82 (dd, *J* = 9.8 and 3.4 Hz, 1H), 3.73-3.79 (m, 1H), 3.36 (s, 3H), 2.65-2.81 (s, 2OH), 1.20 (br s, 12H); ¹³C NMR (100 MHz, CDCl₃): δ_C 179.7, 100.5, 75.3, 74.8, 70.4, 65.4, 55.1, 39.0, 27.1(3), 17.4; Anal. Calcd. for C₁₂H₂₂O₆ (262.30): C, 54.95; H, 8.45. Found: C, 55.01; H, 8.44.

2.2.1. General method for 2,3-di-*O*-esterification of pivaloate **7**

For the preparation of 2,3-di-*O*-esterification of **7**, the direct method was used. In this method, the diol **7** (0.2 g, 0.762 mmol) in basic pyridine solution was added to different acylating agents (2.2 eq.) at 0 °C. A small quantity of 4-dimethylamino pyridine (DMAP) was also added to this solution. Stirring was

continued for several hours at 25 °C until the completion of the reaction. After completion, the reaction was stopped with ice-water and extracted with organic solvent (DCM). Work-up, concentration, and purification through silica gel CC (gradient elution with petroleum ether (PE) to PE-ethyl acetate) gave the desired rhamnopyranoside related novel esters **8a-e** reasonably in good yields.

Methyl 2,3-di-*O*-acetyl-4-*O*-pivaloyl- α -L-rhamnopyranoside (**8a**): Syrup (97%); R_f = 0.51 (PE-ethyl acetate = 10:1); FT-IR (CHCl₃): 1736, 1729(2) cm⁻¹ (CO); ¹H NMR (400 MHz, CDCl₃): δ_H 5.28 (dd, J = 10.2 and 3.4 Hz, 1H), 5.18 (d, J = 3.4 Hz, 1H), 5.03 (t, J = 10.0 Hz, 1H), 4.58 (s, 1H), 3.78-3.85 (m, 1H), 3.35 (s, 3H), 2.10 (s, 3H), 1.91 (s, 3H), 1.19 (d, J = 6.0 Hz, 3H), 1.12 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ_C 177.4, 170.1, 169.7, 98.5, 70.5, 69.9, 69.0, 66.4, 55.1, 38.8, 26.9(3), 20.8, 20.6, 17.3; Anal. Calcd. for C₁₆H₂₆O₈ (346.38): C, 55.48; H, 7.57. Found: C, 55.56; H, 7.60.

Methyl 2,3-di-*O*-methanesulphonyl-4-*O*-pivaloyl- α -L-rhamnopyranoside (**8b**): Thick oil (91%); R_f = 0.53 (PE-ethyl acetate = 10:1); FT-IR (CHCl₃): 1734 (CO), 1362, 1359 cm⁻¹ (SO₂); ¹H NMR (400 MHz, CDCl₃): δ_H 5.00-5.07 (m, 3H), 4.85 (s, 1H), 3.80-3.86 (m, 1H), 3.40 (s, 3H), 3.15 (s, 3H), 3.05 (s, 3H), 1.22 (d, J = 6.3 Hz, 3H), 1.20 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ_C 177.2, 98.5, 75.8, 74.2, 69.4, 66.6, 55.4, 39.0, 38.6, 38.9, 27.1(3), 17.3; Anal. Calcd. for C₁₄H₂₆O₁₀S₂ (418.48): C, 40.18; H, 6.26. Found: C, 40.22; H, 6.34.

Methyl 2,3-di-*O*-octanoyl-4-*O*-pivaloyl- α -L-rhamnopyranoside (**8c**): Yellow liquid (87%); R_f = 0.57 (PE-ethyl acetate = 10:1); FT-IR (CHCl₃): 1744(2), 1737 cm⁻¹ (CO); ¹H NMR (400 MHz, CDCl₃): δ_H 5.24 (dd, J = 9.9 and 3.2 Hz, 1H), 5.20 (d, J = 3.2 Hz, 1H), 5.00 (t, J =

9.8 Hz, 1H), 4.59 (s, 1H), 3.66-3.74 (m, 1H), 3.37 (s, 3H), 2.33 (t, J = 7.7 Hz, 4H), 1.55-1.64 (m, 4H), 1.21-1.36 (br s, 16H), 1.22 (d, J = 6.3 Hz, 3H), 1.11 (s, 9H), 0.86 (t, J = 6.7 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ_C 177.0, 172.6, 172.2, 98.9, 72.2, 69.6, 69.2, 66.0, 55.1, 38.8, 34.1, 31.6, 29.5(4), 29.3, 29.0, 28.8, 25.0, 24.3, 22.6, 27.3(3), 17.3, 14.0, 13.9; Anal. Calcd. for C₂₈H₅₀O₈ (514.69): C, 65.34; H, 9.79. Found: C, 65.40; H, 9.82.

Methyl 2,3-di-*O*-(2-chlorobenzoyl)-4-*O*-pivaloyl- α -L-rhamnopyranoside (**8d**): Syrup (82%); R_f = 0.55 (PE-ethyl acetate = 10:1); FT-IR (CHCl₃): 1735, 1695, 1688 cm⁻¹ (CO); ¹H NMR (400 MHz, CDCl₃): δ_H 7.85 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.26-7.48 (m, 5H), 7.16-7.22 (m, 1H), 5.73 (dd, J = 10.1 and 3.0 Hz, 1H), 5.60 (d, J = 3.0 Hz, 1H), 5.39 (t, J = 9.9 Hz, 1H), 4.83 (s, 1H), 3.95-4.01 (m, 1H), 3.41 (s, 3H), 1.23 (d, J = 6.5 Hz, 3H), 1.08 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ_C 177.3, 164.5, 164.0, 134.1, 134.0, 133.0, 132.9, 131.8(2), 131.1, 130.8, 129.0, 128.6, 126.6, 126.5, 98.3, 71.1, 70.7, 69.9, 66.5, 55.2, 38.7, 26.9(3), 17.4; Anal. Calcd. for C₂₆H₂₈Cl₂O₈ (539.40): C, 57.89; H, 5.23. Found: C, 57.95; H, 5.28.

Methyl 2,3-di-*O*-(4-chlorobenzoyl)-4-*O*-pivaloyl- α -L-rhamnopyranoside (**8e**): Syrup (85%); R_f = 0.56 (PE-ethyl acetate = 10:1); FT-IR (CHCl₃): 1742, 1696, 1680 cm⁻¹ (CO); ¹H NMR (400 MHz, CDCl₃): δ_H 7.97 (d, J = 8.2 Hz, 2H), 7.77 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.3 Hz, 2H), 5.63 (dd, J = 10.1 and 3.1 Hz, 1H), 5.55 (d, J = 3.1 Hz, 1H), 5.36 (t, J = 10.0 Hz, 1H), 4.83 (s, 1H), 4.00-4.07 (m, 1H), 3.46 (s, 3H), 1.28 (d, J = 6.5 Hz, 3H), 1.04 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ_C 177.1, 164.7, 164.4, 140.1, 139.0, 131.2(2), 130.8, 129.4, 129.0, 128.5, 127.0(2), 98.6, 70.9, 70.7, 70.0, 66.3, 55.5, 38.6, 26.9(3), 17.5; Anal. Calcd. for C₂₆H₂₈Cl₂O₈ (539.40): C, 57.89; H, 5.23. Found: C, 57.98; H, 5.29.


The infrared spectrum showed a characteristic carbonyl peak at 1738 cm^{-1} , whereas the OH stretching band was totally absent there and thus indicated attachment of the pivaloyl group in the molecule. Again, its proton NMR showed a characteristic nine-proton singlet at δ 1.17 for the pivaloyl (trimethyl acetyl) group in this molecule. Related other protons appeared in the anticipated positions (Kabir et al., 2002). This fact was also confirmed by analysing its carbon NMR spectrum where pivaloyl-related extra carbon signals (at δ 177.4, 38.7, and 27.1(3)) were observed. More importantly, the proton at C-4 position appears very downfield (at δ 4.79) when compared with its precursor acetonide **5** (at δ 3.28-3.33) (Kabir et al., 2002). This vital observation ultimately confirmed the addition of only one pivaloyl group at position C-4 of this syrupy compound. All these data along with elemental analysis (EA) established the structure of this synthesized syrup as **6**.

In the next step, as shown in Scheme 1, removal of the acetonide functionality was conducted by treating mono-acetonide **6** with AcOH at $\sim 40\text{ }^\circ\text{C}$ for several hours, followed by CC which provided a liquid in good yield. The new appearance of the OH stretching band at $3440\text{-}3190\text{ cm}^{-1}$ in its

infrared spectrum demonstrated the removal of the acetonide group. More evidence in favour of this observation was found from its proton and carbon NMR spectral analyses where methyl signals related to the acetonide group were completely absent. However, a broad singlet exchangeable with D_2O and integrated for two protons at δ 2.65-2.81 was found, and thus, confirmed the deprotection of the acetonide group from the molecule. The rest of the proton and carbon NMR spectra along with DEPT-135 and EA established the structure as **7**.

3.2. Conversion of **7** into novel 2,3-di-O-acyl esters **8a-e**

Due to our continuous interest to search newer derivatives of rhamnopyranoside, we have synthesized five new 2,3-di-O-ester derivatives of pivaloate **7** (as it has free C-2 OH and C-3 OH). The newer five acylating agents used were Ac_2O , MsCl, $\text{C}_7\text{H}_{15}\text{COCl}$, 2-chlorobenzoyl chloride, and 4-chlorobenzoyl chloride. The reaction of the pivaloate **7** and dimolar Ac_2O in the solvent pyridine (catalytic DMAP) followed by CC furnished a faster-moving thick syrup (97%; Scheme 2).



Scheme 2. Preparation of **8a-e**.

The FT-IR spectrum showed carbonyl bands at 1736 and $1729(2)\text{ cm}^{-1}$, and the absence of the OH band indicated the addition of acetyl group(s) in this product. This was initially supported by analysing its proton NMR spectrum wherein two singlets at δ 2.10 and 1.91, each integrated for three protons, were assigned for two acetyl groups. Also, protons of C-2 and C-3 positions were

found to shift downfield at δ 5.18 and 5.29, respectively than the precursor diol **7** (δ 3.90 and 3.82, respectively). This rendered that acetyl groups are incorporated with 2-OH and 3-OH. Further evidence in this favour comes from its ^{13}C NMR spectrum where related carbon signals resonated at δ 170.1, 169.7 (CH_3CO), 20.8, and 20.6 (CH_3CO). DEPT-135 showed the absence of methylene carbons (CH_2) in it.

Corroboration of all the spectral and analytical results confirmed its structure as **8a** (Scheme 2).

Having successful preparation of **8a**, similar reaction, work-up, and purification were employed for diol **7** with mesyl chloride and obtained an oil (91%; Scheme 2). In addition to the CO stretching band (1734 cm^{-1}) it showed characteristic SO_2 stretching bands at 1362 , and 1359 cm^{-1} in its infrared spectrum. Its ^1H NMR showed mesyl characteristic protons at δ 3.15 (s, 3H, SO_2CH_3) and 3.05 (s, 3H, SO_2CH_3). Mesyl groups related to carbon signals were observed at δ 39.0 and 38.6 in its carbon NMR spectrum. Its DEPT spectrum showed an absence of CH_2 carbons. On the basis of all spectroscopic and analytical data, the structure was given as **8b**.

The reaction of the same pivaloate **7** with dimolar octanoyl chloride furnished a liquid in 87% yield (Scheme 2). Its infrared spectrum exhibited characteristic bands at $1744(2)$ and 1737 cm^{-1} (CO). Additional thirty protons in its proton NMR spectrum, compared to its precursor diol **7**, in the aliphatic region [2.33 (t, 4H) 1.55-1.64 (m, 4H) 1.21-1.36 (s, 16H), 0.86 (t, 6H)] were assigned for two octanoyloxy groups. Considering the downfield shift of the protons of C-2 and C-3 positions, ^{13}C NMR, and DEPT-135 analyses this liquid compound was named as **8c**.

Again, treatment of **7** with 2-chlorobenzoyl chloride gave a faster-moving compound (82%; Scheme 2). Its FT-IR showed characteristic bands at 1735 , 1695 , 1688 cm^{-1} (CO), and no bands

in the OH region. In the proton NMR spectrum, it showed a total of eight aromatic protons corresponding to the two chlorobenzoyl groups which were absent in its starting molecule. Compiling all spectral and EA data the compound was confirmed as **8d** (Scheme 2).

Lastly, the reaction of **7** and 4-chlorobenzoyl chloride furnished syrup in 85% (Scheme 2). Its FT-IR spectrum exhibited bands at 1742 , 1696 , and 1680 cm^{-1} . Extra eight aromatic protons appeared in its proton NMR spectrum indicating the presence of two 4-chlorobenzoyl groups in the molecule. ^{13}C NMR spectrum also confirmed related signals at δ 164.7, 164.4 ($2\times\text{CO}$), 140.1, 139.0, 131.2(2), 130.8, 129.4, 129.0, 128.5 and 127.0(2) (Ar-C). It has thus given the structure as **8e**.

3.3. Conformational analysis

The conformational behaviours of bioactive compounds are the basic factor for interactions with receptor proteins (Sawada et al., 2006). In addition to spectroscopic methods quantum mechanical techniques have been used for the structure and conformation elucidation (Noorbacha et al., 2002). Considering biological utility various workers reported that methyl α -L-rhamnopyranoside (**3**) (Matin et al., 2021; Shalaby et al., 1994a), methyl 4-*O*-benzyl- α -L-rhamnopyranoside (**9**) (Pendrill et al., 2014), and methyl 2,3,4-tri-*O*-acetyl- α -L-rhamnopyranoside (**10**) (Shalaby et al., 1994b) exist in $^1\text{C}_4$ conformation from their X-ray crystal structures (Figure 2).




Figure 2. Rhamnopyranoside **4**, **9** and **10**.

In compounds **5** and **6**, the presence of a fused isopropylidene group with the pyranose ring, and in **7-8a-e** the presence of bulky acyl group might have created an extra distortion towards the ring. Hence, we optimized all the compounds **4-8a-e** with the DFT at the RB3LYP level of theory using a 6-311G (*d,p*) basis set. A

similar type of RB3LYP level of theory was used by Sawada et al. (2006) for the conformational study of a biomolecule named neuraminic acid. The optimized structures at 298.15 K (1.0 atm) are shown in Figure 3. All the compounds **4-8a-e** were found to have C1 symmetry.




Figure 3. DFT optimized structures of rhamnopyranoside **4-8a-e**.

The study indicated that the optimized structure of acetonide-protected **5** (chair, **5C**) and **6** (chair, **6C**) didn't match properly with 1C_4 conformation. While rhamnopyranoside **4** and its non-acetonide esters **7-8a-e** exist almost in normal 1C_4 conformation. Their selected ring bond angles and dihedral angles, as shown in Table 1, indicated that in acetonide compound **5** and **6** bond angles at $\angle O5-C1-C2$, $\angle C1-C2-C3$ and $\angle C2-C3-C4$ increased, while at $\angle C4-C5-O5$ and at $\angle C5-O5-C1$ decreased than the parent

rhamnopyranoside **4**. Again, the dihedral angle at $\angle H1-C1-C2-H2$ increased ($\sim 9^\circ$), whereas, decreased considerably at $\angle H2-C2-C3-H3$ ($\sim 17-19^\circ$) and $\angle H3-C3-C4-H4$ ($\sim 14-16^\circ$) compared to **4**. This huge change in dihedral angle caused the deviation of **5** and **6** from regular 1C_4 conformation. With the opening of the acetonide group, as in **7**, both the bond angles and dihedral angles appeared almost similar to the rhamnopyranoside **4** indicating the appearance of regular 1C_4 conformation.

Table 1. Bond angle and dihedral angle of rhamnopyranoside **4-7**.

Compound	Bond angle in degree					
	O5-C1-C2	C1-C2-C3	C2-C3-C4	C3-C4-C5	C4-C5-O5	C5-O5-C1
4	112.5	110.5	110.6	109.7	109.1	116.9
5	113.9	115.5	113.6	110.3	107.3	115.3
6	113.8	115.9	112.7	110.9	107.2	115.2
7	112.8	110.6	110.5	110.1	108.6	115.8
	Dihedral angle in degree					
	H1-C1-C2-H2	H2-C2-C3-H3	H3-C3-C4-H4	H4-C4-C5-H5		
4	74.93	50.69	-176.70	-178.27		
5	85.10	31.58	-162.93	-176.37		
6	84.29	32.71	-160.08	-179.65		
7	75.47	50.27	-174.39	176.45		

*All these values were calculated from 6-311G(++) (*d,p*) sets.

For clarification and validation of the above deviation properly, we have also optimized twist-boat (**5TB**, **6TB**) and boat (**5B**, **6B**) of both the acetonide-protected rhamnopyranosides. However, as shown in

Table 2 and Figure 4, the chair form possessed the minimum energy among the chair, twist-boat, and boat of each of **5** and **6**.

Table 2. Optimized minimum free energy of protected rhamnopyranoside **5** and **6**.

Conformer	Minimum energy (Hartree)	Conformer	Minimum energy (Hartree)
5C	-768.22683451	6C	-1038.90227022
5TB	-768.22510886	6TB	-1038.89662104
5B	-768.22510881	6B	-1038.87585582

*All these values were calculated from 6-311G(++) (*d,p*) basis set. C = chair; TB = twist-boat; B = boat. (1 Hartree = 627.509 kcal/mol)




Figure 4. DFT optimized conformers of protected rhamnopyranoside **4-7**.

The lowest free energy was found for chair conformation for both the compounds (**5C** and **6C**). **5C** bears 1.083 kcal/mol lower energy than **5TB** and **5B** indicating more stability of chair

conformation. However, **5C** didn't completely match with ¹C₄ conformation (Figure 4) having slight distortion at C1, C2, C3, and O5 positions. This is further supported by the observed conformational

relationship between two adjacent carbons such as C1(OMe)-C2(O) has slightly deviated anti, C2(O)-C3(O) deviated to eclipsed (in compound **4** gauche), and C3(O)-C4(O) remains gauche. Actually, it is in between the chair and twist-boat conformation.

Similarly, the lowest free energy was found for the **6C** conformation, which was stabilized by 3.55 kcal/mol from **6TB**, and 16.58 kcal/mol from **6B** (Table 2). The bulky pivaloyl group at the C4 axial position caused more repulsive steric interactions with the C1 axial OCH₃ group in the conformers **6TB** and **6B**. Thus, conformer **6C** with 2,3-*O*-isopropylidene group deviates from proper ¹C₄ conformation (Figure 4) at C1, C2, C3, and O5 positions, and adopts slightly distorted ¹C₄ conformation.

3.4. Molecular orbital analysis

Finally, molecular orbitals of **4-8a-e** in the forms of HOMO (highest occupied

molecular orbital) and LUMO (lowest unoccupied molecular orbital) energy levels, their gaps ($\Delta\varepsilon$) hardness, softness, and dipole moments (DM) are calculated from their optimized structures (Muhammad et al., 2021). These results as presented in Table 3 indicated that acetonide-protected compound **5** (C, TB, and B forms) possess slightly lower $\Delta\varepsilon$ than the non-acetonide compounds **4**, **7**, and **8a-e**. Incorporation of pivaloyl groups at C-4 positions of **5**, as in **6**, slightly increased $\Delta\varepsilon$ value. Removal of acetonide group (**7**) and further addition of acyl groups (**8a-e**) increased their HOMO-LUMO gaps. The higher gaps ($\Delta\varepsilon$) are indicators of lower chemical softness (as observed in Table 3) and higher kinetic stability of the molecules. Interestingly, chair conformations (as in **5C** and **6C**, Figure 5) possess the smallest gaps among the chair (C), twist boat (TB), and boat (B) forms (Table 3) indicating their more reactive nature with higher softness. Dipole moments of **5C** and **6C** were found lower than that of the **5B** and **6B**.

Table 3. Orbitals and related properties of **4-8a-e**.

Mol.	ε HOMO (eV)	ε LUMO (eV)	Gap ($\Delta\varepsilon$, eV)	Hardness (η)	Softness (S)	DM (Debye)
4	-7.2184	0.5165	6.7019	3.351	0.298	2.241
5C	-6.8333	0.8095	6.0238	3.012	0.332	1.141
5TB	-6.8333	0.8095	6.0238	3.012	0.332	1.308
5B	-6.8322	0.8093	6.0229	3.011	0.332	1.309
6C	-7.1990	-0.3257	7.5247	3.762	0.266	2.457
6TB	-7.1552	-0.3820	7.5372	3.769	0.265	2.101
6B	-7.2673	-0.3763	7.6436	3.822	0.262	3.601
7	-7.5697	-0.5257	8.0954	4.048	0.247	3.921
8a	-7.4042	-0.0946	7.5027	3.751	0.267	6.869
8b	-7.7049	-0.0985	7.8034	3.902	0.256	2.382
8c	-7.3068	-0.2054	7.5122	3.756	0.266	8.476
8d	-6.9060	-1.7257	8.6317	4.316	0.232	4.267
8e	-7.1743	-1.8983	9.0726	4.536	0.220	4.917




Figure 5. DOS plot indicating orbital gaps in (i) 5C and (ii) 6C.

4. CONCLUSION

In the present study, selective pivaloylation of rhamnopyranoside **4** was successfully achieved using the acetonide protection-deprotection technique in good yield. The 4-*O*-pivaloate **7** was then used for the preparation of several novel 2,3-di-*O*-esters. The density functional theory (RB3LYP, 6-311G, *d,p*) based study indicated that the acetonide protected **5** and **6** slightly deviated from regular 1C_4 conformation while rhamnopyranoside **4** and its free esters **7-8a-e** exist in almost regular 1C_4 conformation. The synthetic strategy, conformational behaviour, and molecular orbital properties would be able to shed light on understanding their interactions with receptor proteins in the biological system.

5. ACKNOWLEDGEMENT

Financial support from the Research and Publication Cell, University of Chittagong, Bangladesh (2018-19) is gratefully acknowledged.

6. CONFLICT OF INTEREST

The authors have no competing interests.

7. REFERENCES

- Alsarraf, J., Gormand, P., Legault, J., Mihoub, M., & Pichette, A. (2020). Synthesis of a first-generation L-rhamnose dendron. *Tetrahedron Letters* 61(14):151706.
- Awual, M. R. (2017). New type mesoporous conjugate material for selective optical copper(II) ions monitoring & removal from polluted waters. *Chemical Engineering Journal* 307:85-94. <https://doi.org/10.1016/j.cej.2016.07.110>
- Bukowicki, J., Wawer, A., & Paradowska, K. (2015). Conformational analysis of gentiobiose using genetic algorithm search and GIAO DFT calculations with ${}^{13}C$ CPMAS NMR as a verification method. *Journal of Carbohydrate Chemistry* 34(3):145-162, <http://dx.doi.org/10.1080/07328303.2015.1016230>
- Dhavale, D. D., & Matin, M. M. (2005). Piperidine homoazasugars: Natural occurrence, synthetic aspects and biological activity study. *Arkivoc*, 2005(3):110-132. <https://doi.org/10.3998/ark.5550190.0006.314>

- Elmaidomy, A. H., Mohammed, R., Owis A. I., Hetta, M. H., AboulMagd, A. M., Siddique, A. B., Abdelmohsen, U. R., Rateb, M. E., Sayed, K. A. E., & Hassan, H. M. (2020). Triple-negative breast cancer suppressive activities, antioxidants and pharmacophore model of new acylated rhamnopyranoses from *Premna odorata*. RSC Advances 10:10584-10598. <https://doi.org/10.1039/D0RA01697G>
- Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Petersson, G. A., & Nakatsuji, H. (2013). Gaussian 09, Gaussian, Inc. (Wallingford CT).
- Gregurick, K. S., & Kafafi, S. A. (1999). Computation of the electronic and spectroscopic properties of carbohydrates using novel density functional and vibrational self-consistent field methods. Journal of Carbohydrate Chemistry 18(8):867-890. <http://dx.doi.org/10.1080/07328309908544041>
- Hevey, R. (2019). Strategies for the development of glycomimetic drug candidates. Pharmaceuticals 12(2):55. <https://doi.org/10.3390/ph12020055>
- Jacob, J. N., & Tazawa, M. (2012). Glucose–aspirin: Synthesis and in vitro anti-cancer activity studies. Bioorganic & Medicinal Chemistry Letters 22:3168-3171. <https://doi.org/10.1016/j.bmcl.2012.03.053>
- Kabir, A. K. M. S., & Matin, M. M. (1994). Regioselective acylation of a derivative of L-rhamnose using the dibutyltin oxide method. Journal of the Bangladesh Chemical Society, 7(1):73-79.
- Kabir, A. K. M. S., & Matin, M. M. (1996). Selective pivaloylation of some D-glucose derivatives. Chittagong University Studies, Part II: Science 20(2):105-111.
- Kabir, A. K. M. S., & Matin, M. M. (1997). Regioselective monoacylation of a derivative of L-rhamnose. Journal of Bangladesh Academy of Sciences 21(1):83-88.
- Kabir, A. K. M. S., Matin, M. M., Hossain, A., & Rahman, M. S. (2002). Synthesis and antimicrobial activities of some acylated derivatives of L-rhamnose. The Chittagong University Journal of Science 26(1&2):35-44.
- Kabir, A. K. M. S., Matin, M. M., Hossain, A., & Sattar, M. A. (2003). Synthesis and antimicrobial activities of some rhamnopyranoside derivatives. Journal of the Bangladesh Chemical Society 16(2):85-93.
- Kazmi, I., Rahman, M., Afzal, M., Gupta, G., Saleem, S., Afzal, O., Shaharyar, M. A., Nautiyal, U., Ahmed S., & Anwar, F. (2012). Anti-diabetic potential of ursolic acid stearyl glucoside: A new triterpenic glycosidic ester from *Lantana camara*. Fitoterapia 83:142-146. <https://doi.org/10.1016/j.fitote.2011.10.004>
- Lawandi, J., Rocheleau, S., & Moitessier, N. (2016). Regioselective acylation, alkylation, silylation and glycosylation of monosaccharides. Tetrahedron 72:6283-6319.
- Liu, N., Tian, X., Ding, Z., Zhou, Y., Zhang, W., Wang, Q., Zhang, Y., Gu, Y., & Zhang, J. (2017). Synthesis of aryl α -O-L-rhamnopyranoside by two-step reaction in one pot. Journal

- of Carbohydrate Chemistry 36:220-234.
<http://dx.doi.org/10.1080/07328303.2017.1390578>
- Luo, X. -P., Du, L. -H., He, F., & Zhou, C. H. (2013). Controllable regioselective acylation of flavonoids catalyzed by lipase in microreactors. Journal of Carbohydrate Chemistry 32(7):450-462.
<http://dx.doi.org/10.1080/07328303.2013.843095>
- Mainal, A., Hashim, R., & Mahmood, K. H. (2001). Molecular modeling of some mono- and disaccharides. Malaysian Journal of Science 20:77-90.
- Matin, M. M., Sharma, T., Sabharwal, S. G., & Dhavale, D. D. (2005). Synthesis and evaluation of glycosidase inhibitory activity of 5-hydroxy substituted isofagomine analogues. Organic & Biomolecular Chemistry 3(9):1702-1707.
<https://doi.org/10.1039/b418283a>
- Matin, M. M. (2006). *N*-Butylation and -acetylation of a sugar derived β -aminoester. The Chittagong University Journal of Science 30(1):35-39.
- Matin, M. M., Ibrahim, M., & Rahman, M. S. (2008). Antimicrobial evaluation of methyl 4-*O*-acetyl- α -L-rhamnopyranoside derivatives. The Chittagong University Journal of Biological Sciences 3(1&2):33-43.
<http://dx.doi.org/10.3329/cujbs.v3i1.13404>
- Matin, M. M., & Ibrahim, M. (2010). Synthesis of some methyl 4-*O*-octanoyl- α -L-rhamnopyranoside derivatives. Journal of Applied Sciences Research 6(10):1527-1532.
- Matin, M. M. (2014). Synthesis and antimicrobial study of some methyl 4-*O*-palmitoyl- α -L-rhamnopyranoside derivatives. Orbital: The Electronic Journal of Chemistry 6(1):20-28.
<https://doi.org/10.17807/orbital.v6i1.553>
- Matin, M. M., Nath, A. R., Saad, O., Bhuiyan, M. M. H., Kadir, F. A., Abd Hamid, S. B., Alhadi, A. A., Ali, M. E., & Yehye, W. A. (2016). Synthesis, PASS-predication and *in vitro* antimicrobial activity of benzyl 4-*O*-benzoyl- α -L-rhamnopyranoside derivatives. International Journal of Molecular Sciences 17(9):1412.
<https://doi.org/10.3390/ijms17091412>
- Matin, M. M., Bhuiyan, M. M. H., Kabir, E., Sanallah, A. F. M., Rahman, M. A., Hossain, M. E., & Uzzaman, M. (2019a). Synthesis, characterization, ADMET, PASS predication, and antimicrobial study of 6-*O*-lauroyl mannopyranosides. Journal of Molecular Structure 1195:189-197.
<https://doi.org/10.1016/j.molstruc.2019.05.102>
- Matin, M. M., Bhattacharjee, S. C., Chakraborty, P., & Alam, M. S. (2019b). Synthesis, PASS predication, *in vitro* antimicrobial evaluation and pharmacokinetic study of novel *n*-octyl glucopyranoside Esters. Carbohydrate Research 485:107812.
<https://doi.org/10.1016/j.carres.2019.107812>
- Matin, M. M., & Chakraborty, P. (2020). Synthesis, spectral and DFT characterization, PASS predication, antimicrobial, and ADMET studies of some novel mannopyranoside esters. Journal of Applied Science & Process Engineering 7(2):572-586.
<https://doi.org/10.33736/jaspe.2603>

2020

- Matin, M. M., Chakraborty, P., Alam, M. S., Islam, M. M., & Hanee, U. (2020a). Novel mannopyranoside esters as sterol 14 α -demethylase inhibitors: Synthesis, PASS predication, molecular docking, and pharmacokinetic studies. *Carbohydrate Research* 496:108130. <https://doi.org/10.1016/j.carres.2020.108130>
- Matin, M. M., Roshid, M. H. O., Bhattacharjee, S. C., & Azad, A. K. M. S. (2020b). PASS Predication, antiviral, *in vitro* antimicrobial, and ADMET studies of rhamnopyranoside esters. *Medical Research Archives* 8(7):2165. <https://doi.org/10.18103/mra.v8i7.2165>
- Matin, M. M., Hasan, M.S., Uzzaman, M., Bhuiyan, M. M. H., Kibria, S. M., Hossain, M. E., & Roshid, M. H. O. (2020c). Synthesis, spectroscopic characterization, molecular docking, and ADMET studies of mannopyranoside esters as antimicrobial agents. *Journal of Molecular Structure* 1222:128821. <https://doi.org/10.1016/j.molstruc.2020.128821>
- Matin, M. M., Uzzaman, M., Chowdhury, S. A., & Bhuiyan, M. M. H. (2020d). *In vitro* antimicrobial, physicochemical, pharmacokinetics and molecular docking studies of benzoyl uridine esters against SARS-CoV-2 main protease. *Journal of Biomolecular Structure and Dynamics*. <http://dx.doi.org/10.1080/07391102.2020.1850358>; PMID: 33297848; PMCID: PMC7738211.
- Matin, M. M., Islam, N., Siddika, A., & Bhattacharjee, S. C. (2021). Regioselective synthesis of some rhamnopyranoside esters for PASS predication, and ADMET studies. *Journal of the Turkish Chemical Society Section A: Chemistry* 8(1):363-374. <https://doi.org/10.18596/jotcsa.829658>
- Muhammad, D., Matin, M. M., Miah, S. M. R., & Devi, P. (2021). Synthesis, Antimicrobial, and DFT studies of some benzyl 4-O-acyl- α -L-rhamnopyranosides. *Orbital: The Electronic Journal of Chemistry* 13(3):250-258. <http://dx.doi.org/10.17807/orbital.v13i3.1614>
- Noorbatcha, I., Hassan, S., Hamid, A., Hadi, A., & Awang, K. (2002). *Ab-initio* geometry-optimization and NMR studies of chemical constituents of *Piper sarmentosum*. *Malaysian Journal of Science* 21:143-147.
- Pendrill, R., Eriksson, L., & Widmalm, G. (2014). Methyl 4-O-benzyl- α -L-rhamnopyranoside. *Acta Cryst. Sect. E*. <https://doi.org/10.1107/S1600536814007922>
- Shalaby, M. A., Fronczek, F. R., & Younathan, E. S. (1994a). Structural analysis of methyl α -L-rhamnopyranoside in the solid state. *Carbohydrate Research* 258:267-274. [https://doi.org/10.1016/0008-6215\(94\)84092-X](https://doi.org/10.1016/0008-6215(94)84092-X)
- Shalaby, M. A., Fronczek, F. R., & Younathan, E. S. (1994b). Conformational features of rhamnopyranose derivatives. The molecular structure of methyl 2,3,4-tri-O-acetyl- α -L-rhamnopyranoside. *Carbohydrate Research* 264(2):173-180. [https://doi.org/10.1016/S0008-6215\(05\)80003-5](https://doi.org/10.1016/S0008-6215(05)80003-5)
- Sawada, T., Hashimoto, T., Nakano, H.,

Shigematsu, M., Ishida, H., & Kiso, M. (2006). Conformational study of α -N-acetyl-D-neuraminic acid by density functional theory. *Journal of Carbohydrate Chemistry* 25(5):387-405.

<http://dx.doi.org/10.1080/07328300600778801>

Yadav, S., Yadava, S., & Yadav, K. D. S. (2013). Purification and characterization of α -L-rhamnosidase from *Penicillium corylopholum* MTCC-2011. *Process Biochemistry* 48:1348–1354.

Zhang, J., Fu, J., Chen, X., Gu, Y., & Tang, J. (2008). 4-Nitro-phenyl α -L-rhamnopyranoside hemihydrate. *Acta Crystallogr. Sect. E Struct. Rep. Online*, 264:o714.